ReviewJournal of clinical medicine2024
The Therapeutic Potential of GLP-1 Receptor Agonists in the Management of Hidradenitis Suppurativa: A Systematic Review of Anti-Inflammatory and Metabolic Effects.
Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A Systematic Review of the Clinical Impact of GLP-1 Receptor Agonists in Hidradenitis Suppurativa.American journal of clinical dermatology · 2026Pooled it
- Dietary patterns, metabolic pathways and metainflammation in hidradenitis suppurativa: a systematic review.Frontiers in immunology · 2026Pooled it
- The Expanding Role of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Agonists in Dermatology: From Immunometabolism to Clinical Practice.Dermatology and therapy · 2026Review
- Hidradenitis Suppurativa from Preconception to Lactation: Clinical Treatment Decision-Making Review.Dermatology and therapy · 2026Review
- American Academy of Dermatology 2026 Annual Meeting: Updates in Hidradenitis Suppurativa Medical Management.Dermatology and therapy · 2026Review
- Association of Glucagon-Like Peptide-1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes.Obesity (Silver Spring, Md.) · 2026Article
- Black-market weight loss injectables in Hidradenitis Suppurativa: a single-centre survey.Irish journal of medical science · 2026Article
- GLP-1RAs and cardiovascular risk in HS: concerns about follow-up time and effect estimates.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Hidradenitis suppurativa: epidemiology, diagnosis, molecular pathogenesis and therapy.Molecular biomedicine · 2026Review
- Reducing Unmet Needs in Hidradenitis Suppurativa by Including the Hair Follicle Among an Arsenal of Targets.Experimental dermatology · 2026Review
- Marked improvement in severe hidradenitis suppurativa following tirzepatide therapy: a case report.International journal of women's dermatology · 2026Article
- Balancing the benefits and risks of GLP-1 receptor agonists: a clinical guide for shared decision-making.EClinicalMedicine · 2026Review
- Hidradenitis Suppurativa Changes Major Life Decisions of Affected Patients: A Cross-sectional Study.Acta dermato-venereologica · 2026Article
- A Neuroendocrine-Immune Model of Hidradenitis Suppurativa: Mechanistic Insights into Pain, Pruritus, and Hormonal Triggers.Journal of clinical medicine · 2026Review
- Review
- Rapid remission of Hailey-Hailey disease with tirzepatide therapy: A case report.JAAD case reports · 2026Article
- Effects of GLP-1 Agonists on Patients with Hidradenitis Suppurativa: A Systematic Review.Journal of clinical medicine · 2026Review
- The Therapeutic Potential of Glucagon-Like Peptide-1 Receptor Agonists in Psoriasis and Hidradenitis Suppurativa.The Journal of clinical and aesthetic dermatology · 2026Review
- Meta-inflammation in Hidradenitis suppurativa: from pathogenic evidence to therapeutic approaches.Frontiers in immunology · 2026Review
- Hidradenitis suppurativa and psoriasis: shared immunological links with metabolic-associated steatotic liver disease.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.